KBC Group NV Buys 20,013 Shares of Danaher Corporation $DHR

KBC Group NV increased its stake in Danaher Corporation (NYSE:DHR) by 8.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 264,067 shares of the conglomerate’s stock after purchasing an additional 20,013 shares during the period. KBC Group NV’s holdings in Danaher were worth $52,165,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Nuveen LLC acquired a new position in shares of Danaher during the first quarter worth about $833,941,000. Generation Investment Management LLP lifted its stake in Danaher by 56.2% in the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after acquiring an additional 1,787,522 shares in the last quarter. Invesco Ltd. boosted its position in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after acquiring an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. boosted its position in Danaher by 290.6% during the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock worth $295,550,000 after acquiring an additional 1,072,617 shares during the last quarter. Finally, Parnassus Investments LLC grew its stake in shares of Danaher by 23.3% during the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock worth $784,745,000 after acquiring an additional 722,636 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Guggenheim reissued a “buy” rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Evercore ISI increased their price objective on shares of Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Wall Street Zen downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Barclays upped their target price on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Eighteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $243.39.

Danaher Trading Up 1.8%

Shares of NYSE:DHR opened at $219.60 on Thursday. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The company has a market capitalization of $155.11 billion, a P/E ratio of 45.28, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The company has a 50-day simple moving average of $204.76 and a 200 day simple moving average of $200.77.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the prior year, the company earned $1.71 earnings per share. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s payout ratio is 26.39%.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares of the company’s stock, valued at $552,352.50. This represents a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Teri List sold 2,778 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 11.20% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.